Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. Daniel Pollyea

Leukemia · CU Anschutz Medical Campus

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    JWDr. Justin Watts

    Dr. Justin Watts

    Hematology & Oncology · Leukemia
    University of Miami
    justinw

    Research

    Phase I first-in-human dose-expansion study of the oral SF3B1 modulator H3B-8800 in lower-risk myelodysplastic syndrome

    2025

    Via Leukemia Research

    Research

    Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

    2025

    Via Journal of Hematology & Oncology

    Research

    Adult leukemia in Florida 2010–2019: diverse population epidemiology

    2025

    Via Blood Neoplasia

    Research

    Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML

    2025

    Via NPJ Precision Oncology

    Research

    Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report

    2025

    Via Leukemia Research Reports

    Research

    Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B-8800 in lower-risk myelodysplastic syndrome

    2025

    Via Leukemia Research

    Research

    Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia

    2025

    Via American Journal of Hematology

    Research

    Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML

    2025

    Via bioRxiv

    Research

    Balancing Activation and Repression: CoREST-p300 Antagonism Controls Retinoic Acid-Driven Differentiation in AML

    2025

    Via bioRxiv

    Research

    Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

    2025

    Via Blood Advances

    Research

    Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort

    2025

    Via Journal of Hematology & Oncology

    Research

    Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia

    2024

    Via Blood Neoplasia

    Research

    Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)

    2024

    Via Leukemia & Lymphoma

    Research

    Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

    2024

    Via Blood Advances

    Research

    Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms

    2024

    Via Therapeutic Advances in Hematology